More Ways to Connect
  LinkedIn Twitter YouTube Instagram
Nathan Schmulewitz, MD (left), and Alberto Espay, MD, are collaborating on a clinical trial that investigates a new method of delivering a Parkinson's disease medication.
Parkinson's Patient Speaks at UC Health Research Week
Janice Yelton, a participant in a Parkinson's medical delivery trial at UC, spoke about her experience at the 2011 UC Health University Hospital Research Week kickoff May 23.

Nathan Schmulewitz, MD (left), and Alberto Espay, MD, are collaborating on a clinical trial that investigates a new method of delivering a Parkinson's disease medication.
Back Next
Publish Date: 08/05/10
Media Contact: AHC Public Relations, (513) 558-4553
Patient Info: For information on the clinical trial, call (513) 475-8730.
PDF download
RSS feed
related news
share this
UC HEALTH LINE: Trial Studies New Way to Deliver Parkinson's Medication

CINCINNATIóMost medications for Parkinsonís disease are taken orally, at certain times of the day. But doctors at UC Health University Hospital are participating in a clinical trial that significantly changes the Parkinsonís drug-delivery model.

Parkinsonís disease is a chronic, degenerative neurological disorder in which certain dopamine-producing cells in a region of the brain begin to die. When these cells die, neurons in the brain fire erratically, leaving patients less able to direct or control their movements.

Abbott's Levodopa-Carbidopa Intestinal Gel treatment system (referred to as Duodopa in Europe, where it is commercially available) feeds levodopa (the precursor of dopamine) into the upper intestine via a small tube inserted directly into the first part of the small bowel, or duodenum. The medication is suspended as a stable gel from a cassette worn outside the body. The programmable pump allows the patient or physician to adjust the delivery of medication.

The system is in a phase 3 clinical trial, the final step of testing before study results are submitted to the Food and Drug Administration (FDA) to obtain a New Drug Application. Phase 3 trials are multi-center trials on large patient groups.

"With the way we administer most other Parkinsonís medications, the stimulation to dopamine receptors is given, then taken away, in multiple cycles throughout the day,Ē says UC Health neurologist Alberto Espay, MD, a member of the UC Neuroscience Institute at University Hospital. "With this system, weíre basically bathing the patient in dopamine at all times, at a more physiologic rate, eliminating the artificial variability of stimulation that is otherwise inflicted upon the brain.Ē

If found to be safe and effective and approved by the FDA, the system may offer the greatest potential for patients with advanced stage Parkinsonís disease where oral treatments are no longer effective. With Parkinsonís, Espay says, there is a wearing-off phenomenon as the disease progresses and intervals between doses need to become progressively shorter to minimize the re-emergence of Parkinsonís symptoms.

Espay works in cooperation with UC Health physician Nathan Schmulewitz, MD, who performs the tube insertion procedure at University Hospital. Patients typically are hospitalized for about a week for testing before the procedure and recuperate in the hospital afterward.

Don Truesdale, 46, of Maineville, underwent the procedure at University Hospital in March 2009. He wears the cassette 16 hours a day, taking it off to sleep at night.

"The whole experience at University Hospital was top-notch,Ē he says. "Everyone from the physical therapy assistants all the way up was tremendous.Ē

 back to list | back to top